Control theory prediction of resolved Cheyne-Stokes respiration in heart failure

Scott A. Sands, Bradley A. Edwards, Kirk Kee, Christopher Stuart-Andrews, Elizabeth M. Skuza, Teanau Roebuck, Anthony Turton, Garun S. Hamilton, Matthew T. Naughton, Philip J. Berger

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Cheyne-Stokes respiration (CSR) foretells deleterious outcomes in patients with heart failure. Currently, the size of therapeutic intervention is not guided by the patient's underlying pathophysiology. In theory, the intervention needed to resolve CSR, as a control system instability (loop gain >1), can be predicted knowing the baseline loop gain and how much it falls with therapy. In 12 patients with heart failure, we administered an inspiratory carbon dioxide fraction of 1-3% during CSR (n=95 interventions) as a means to reduce loop gain. We estimated the loop gain on therapy (LGtherapy), using the baseline loop gain (using hyperpnoea length/cycle length) and its expected reduction (18% per 1% inspired carbon dioxide), and tested the specific hypothesis that LGtherapy predicts CSR persistence (LGtherapy >1) versus resolution (LGtherapy <1). As predicted, when LGtherapy >1.0, CSR continued during therapy in 23 out of 25 (92%) trials. A borderline loop gain zone (0.8<LGtherapy<1) yielded an unpredictable outcome, while LGtherapy <0.8 consistently yielded CSR resolution (37 out of 37 trials). A threshold of LGtherapy=0.9 determined outcome in 76 out of 95 (80%) trials. We establish proof-of-concept that control theory provides predictive insight into CSR resolution in heart failure. Thus, we now have a means to calculate the size of interventions needed to ameliorate CSR on a patient-by-patient basis.

Original languageEnglish
Pages (from-to)1351-1359
Number of pages9
JournalEuropean Respiratory Journal
Volume48
Issue number5
DOIs
Publication statusPublished - 1 Nov 2016

Cite this

Sands, Scott A. ; Edwards, Bradley A. ; Kee, Kirk ; Stuart-Andrews, Christopher ; Skuza, Elizabeth M. ; Roebuck, Teanau ; Turton, Anthony ; Hamilton, Garun S. ; Naughton, Matthew T. ; Berger, Philip J. / Control theory prediction of resolved Cheyne-Stokes respiration in heart failure. In: European Respiratory Journal. 2016 ; Vol. 48, No. 5. pp. 1351-1359.
@article{fed608703163446db8ff56046e040c8e,
title = "Control theory prediction of resolved Cheyne-Stokes respiration in heart failure",
abstract = "Cheyne-Stokes respiration (CSR) foretells deleterious outcomes in patients with heart failure. Currently, the size of therapeutic intervention is not guided by the patient's underlying pathophysiology. In theory, the intervention needed to resolve CSR, as a control system instability (loop gain >1), can be predicted knowing the baseline loop gain and how much it falls with therapy. In 12 patients with heart failure, we administered an inspiratory carbon dioxide fraction of 1-3{\%} during CSR (n=95 interventions) as a means to reduce loop gain. We estimated the loop gain on therapy (LGtherapy), using the baseline loop gain (using hyperpnoea length/cycle length) and its expected reduction (18{\%} per 1{\%} inspired carbon dioxide), and tested the specific hypothesis that LGtherapy predicts CSR persistence (LGtherapy >1) versus resolution (LGtherapy <1). As predicted, when LGtherapy >1.0, CSR continued during therapy in 23 out of 25 (92{\%}) trials. A borderline loop gain zone (0.8<LGtherapy<1) yielded an unpredictable outcome, while LGtherapy <0.8 consistently yielded CSR resolution (37 out of 37 trials). A threshold of LGtherapy=0.9 determined outcome in 76 out of 95 (80{\%}) trials. We establish proof-of-concept that control theory provides predictive insight into CSR resolution in heart failure. Thus, we now have a means to calculate the size of interventions needed to ameliorate CSR on a patient-by-patient basis.",
author = "Sands, {Scott A.} and Edwards, {Bradley A.} and Kirk Kee and Christopher Stuart-Andrews and Skuza, {Elizabeth M.} and Teanau Roebuck and Anthony Turton and Hamilton, {Garun S.} and Naughton, {Matthew T.} and Berger, {Philip J.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1183/13993003.00615-2016",
language = "English",
volume = "48",
pages = "1351--1359",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "5",

}

Control theory prediction of resolved Cheyne-Stokes respiration in heart failure. / Sands, Scott A.; Edwards, Bradley A.; Kee, Kirk; Stuart-Andrews, Christopher; Skuza, Elizabeth M.; Roebuck, Teanau; Turton, Anthony; Hamilton, Garun S.; Naughton, Matthew T.; Berger, Philip J.

In: European Respiratory Journal, Vol. 48, No. 5, 01.11.2016, p. 1351-1359.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Control theory prediction of resolved Cheyne-Stokes respiration in heart failure

AU - Sands, Scott A.

AU - Edwards, Bradley A.

AU - Kee, Kirk

AU - Stuart-Andrews, Christopher

AU - Skuza, Elizabeth M.

AU - Roebuck, Teanau

AU - Turton, Anthony

AU - Hamilton, Garun S.

AU - Naughton, Matthew T.

AU - Berger, Philip J.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Cheyne-Stokes respiration (CSR) foretells deleterious outcomes in patients with heart failure. Currently, the size of therapeutic intervention is not guided by the patient's underlying pathophysiology. In theory, the intervention needed to resolve CSR, as a control system instability (loop gain >1), can be predicted knowing the baseline loop gain and how much it falls with therapy. In 12 patients with heart failure, we administered an inspiratory carbon dioxide fraction of 1-3% during CSR (n=95 interventions) as a means to reduce loop gain. We estimated the loop gain on therapy (LGtherapy), using the baseline loop gain (using hyperpnoea length/cycle length) and its expected reduction (18% per 1% inspired carbon dioxide), and tested the specific hypothesis that LGtherapy predicts CSR persistence (LGtherapy >1) versus resolution (LGtherapy <1). As predicted, when LGtherapy >1.0, CSR continued during therapy in 23 out of 25 (92%) trials. A borderline loop gain zone (0.8<LGtherapy<1) yielded an unpredictable outcome, while LGtherapy <0.8 consistently yielded CSR resolution (37 out of 37 trials). A threshold of LGtherapy=0.9 determined outcome in 76 out of 95 (80%) trials. We establish proof-of-concept that control theory provides predictive insight into CSR resolution in heart failure. Thus, we now have a means to calculate the size of interventions needed to ameliorate CSR on a patient-by-patient basis.

AB - Cheyne-Stokes respiration (CSR) foretells deleterious outcomes in patients with heart failure. Currently, the size of therapeutic intervention is not guided by the patient's underlying pathophysiology. In theory, the intervention needed to resolve CSR, as a control system instability (loop gain >1), can be predicted knowing the baseline loop gain and how much it falls with therapy. In 12 patients with heart failure, we administered an inspiratory carbon dioxide fraction of 1-3% during CSR (n=95 interventions) as a means to reduce loop gain. We estimated the loop gain on therapy (LGtherapy), using the baseline loop gain (using hyperpnoea length/cycle length) and its expected reduction (18% per 1% inspired carbon dioxide), and tested the specific hypothesis that LGtherapy predicts CSR persistence (LGtherapy >1) versus resolution (LGtherapy <1). As predicted, when LGtherapy >1.0, CSR continued during therapy in 23 out of 25 (92%) trials. A borderline loop gain zone (0.8<LGtherapy<1) yielded an unpredictable outcome, while LGtherapy <0.8 consistently yielded CSR resolution (37 out of 37 trials). A threshold of LGtherapy=0.9 determined outcome in 76 out of 95 (80%) trials. We establish proof-of-concept that control theory provides predictive insight into CSR resolution in heart failure. Thus, we now have a means to calculate the size of interventions needed to ameliorate CSR on a patient-by-patient basis.

UR - http://www.scopus.com/inward/record.url?scp=84994316523&partnerID=8YFLogxK

U2 - 10.1183/13993003.00615-2016

DO - 10.1183/13993003.00615-2016

M3 - Article

VL - 48

SP - 1351

EP - 1359

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 5

ER -